NextCure, Inc. (NASDAQ:NXTC) Shares Shorted: Short Interest Up 102.7% in September

NextCure, Inc. (NASDAQ:NXTC) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 213,309 shares, an increase of 102.7% from the September 15th total of 105,240 shares. Based on an average daily volume of 114,775 shares, the short-interest ratio is currently 1.9 days. Currently, 6.7% of the company’s shares are short sold.

Insider Activity at NextCure

In other NextCure news, major shareholder Adar1 Capital Management, Llc purchased 292,850 shares of the stock in a transaction dated Thursday, July 30th. The stock was acquired at an average cost of $4.93 per share, for a total transaction of $1,443,750.50. Following the acquisition, the insider owned 686,116 shares in the company, valued at $3,382,551.88. This trade represents a 74.47% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders acquired 346,761 shares of company stock valued at $1,710,807. Corporate insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On NextCure

An institutional investor recently raised its stake in NextCure stock. Renaissance Technologies LLC grew its holdings in NextCure, Inc. (NASDAQ:NXTC) by 80.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,534 shares of the company’s stock after acquiring an additional 26,900 shares during the period. Renaissance Technologies LLC owned about 1.68% of NextCure worth $647,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 42.65% of the company’s stock.

NextCure Stock Up 1.0%

NASDAQ NXTC traded up $0.06 during trading on Wednesday, hitting $6.34. The stock had a trading volume of 6,947 shares, compared to its average volume of 732,337. The company has a market capitalization of $22.89 million, a PE ratio of -0.73 and a beta of 1.33. The firm has a 50 day moving average price of $6.38 and a 200 day moving average price of $6.49. NextCure has a twelve month low of $1.55 and a twelve month high of $15.74.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85).

Wall Street Analyst Weigh In

Several research analysts have weighed in on NXTC shares. Wall Street Zen raised shares of NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. HC Wainwright restated a “buy” rating on shares of NextCure in a report on Thursday, August 13th. Finally, Weiss Ratings raised shares of NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $19.00.

About NextCure

NextCure, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer. The company’s research is centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack tumor cells, with the goal of addressing limitations associated with existing cancer immunotherapies.

NextCure’s pipeline has included investigational antibody-based therapies and other immune-modulating programs targeting mechanisms that can suppress immune responses in the tumor microenvironment.